Stockscreener 앱 받기
21.56
0.87%
-0.17
전일 마감가:
$21.73
열려 있는:
$21.8
하루 거래량:
354.58K
Relative Volume:
0.42
시가총액:
$885.50M
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
14.87
EPS:
1.45
순현금흐름:
$173.19M
1주 성능:
+5.80%
1개월 성능:
-6.06%
6개월 성능:
-13.18%
1년 성능:
-20.60%
1일 변동 폭
$21.43
$22.09
1주일 범위
$20.43
$22.09
52주 변동 폭
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.55 | 893.10M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.36 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.16 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.97 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.24 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira BioSciences Highlights Positive Impact of NOPAIN Act on Non-Opioid Pain Management in New Survey Findings - Quiver Quantitative
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira hands new hires $21.02 stock options and RSUs - Stock Titan
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
2026-02-08 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
NJ Judges Tosses Pacira Investor Suit Over Patent Loss - Law360
2026-02-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out | NDAQ:PCRX | Press Release - Stockhouse
Avoiding Lag: Real-Time Signals in (PCRX) Movement - Stock Traders Daily
Pacira BioSciences (PCRX) Stock Price, News & Analysis - MarketBeat
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com - Investing.com Nigeria
Pacira BioSciences SVP Lauren Riker sells $83k in stock - Investing.com
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares - MarketBeat
Pacira BioSciences officer Williams sells $269k in shares By Investing.com - Investing.com Canada
Pacira BioSciences officer Williams sells $269k in shares - Investing.com
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
2026-02-01 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
In A Strategic Move, Samit Hirawat Acquires Pacira BioSciences Stock Options Worth $9K: Enhancing Value - Benzinga
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Gap Down: What is Deluxe Corporations valuation compared to sectorQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com - Investing.com Nigeria
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Pacira BioSciences Inc.’s technical support levels2025 Sector Review & Technical Buy Zone Confirmations - mfd.ru
Pacira appoints Samit Hirawat to board of directors - TipRanks
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Pacira BioSciences appoints Samit Hirawat to board of directors - Investing.com
Bristol Myers drug development leader joins Pacira board - Stock Titan
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unveiling a 44.95% Potential Upside for Investors - DirectorsTalk Interviews
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. stock deliver shareholder valueDebt-to-Equity Ratio Analysis & Smarter Trades Backed by Machine Learning - bollywoodhelpline.com
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途牛牛
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
10.18%
자본화:
|
볼륨(24시간):